Refractive Surgery by the Numbers: How Many People Are Having LASIK, EVO ICL, and Other Vision Correction Procedures? An inside look at the numbers, trends, technologies, and future of vision correction in 2026.


November 20, 2026
Refractive surgery has come a remarkable distance since the first radial keratotomy (RK) procedures of the 1970s and 1980s. Today, patients have more and better options than ever to reduce or eliminate their dependence on glasses and contact lenses.
From LASIK and PRK to EVO ICL, refractive lens exchange (RLE), and premium cataract surgery, today’s technology allows surgeons to customize vision correction based on a patient’s age, prescription, eye anatomy, and lifestyle.
But how many people actually undergo these procedures? Which are growing, which are declining, and what might the future hold?
1. How Many Refractive Surgeries Are Performed Each Year?
4.9–5.2 million refractive procedures were projected to be performed worldwide in 2025, according to industry estimates from Market Scope and STAAR Surgical. These figures primarily include LASIK, PRK, SMILE, and implantable contact lenses such as EVO ICL-but importantly not cataracts, whose numbers dwarf LASIK, in that total. The United States accounts for hundreds of thousands of laser vision correction procedures annually, although exact totals vary by source and year.
Cataract surgery represents a much larger market:
- 5.2 million cataract surgeries in the United States in 2025.
- 33 million cataract surgeries worldwide.
- Approximately 21% of U.S. cataract procedures used premium intraocular lenses, but that percentage is much higher at SHARPEVISION.
- Approximately 15% of cataract procedures worldwide used premium lenses. That translates into roughly 1.1 million premium cataract procedures annually in the United States and nearly 5 million worldwide.
These are estimates of procedures performed on individual eyes, not numbers of patients. Premium cataract surgery (using advanced technology lenses) is counted separately from elective refractive surgery to avoid misleading comparisons.
2. LASIK: Still the Most Recognized Name in Vision Correction
LASIK (Laser-Assisted In Situ Keratomileusis) has been performed in the United States since FDA approval in 1999.
LASIK reshapes the cornea using an excimer laser, typically after creating a thin corneal flap with a femtosecond laser.
Typical candidates:
- Age: 18 and older, most commonly 20–45.
- Nearsightedness: approximately −1.00 to −10.00 diopters (D).
- Farsightedness: generally up to +4.00 to +6.00 D.
- Astigmatism: often up to 5.00–6.00 D, depending on the laser and anatomy.
LASIK remains popular because of its rapid visual recovery, minimal discomfort, and excellent predictability in appropriately selected patients. However, LASIK volumes have declined in recent years, particularly in the United States. A September 2026 STAAR Surgical market report estimated a 52% reduction in U.S. laser procedure volume since 2022. Economic uncertainty, competition from newer procedures, and changing patient preferences may all contribute.
3. PRK: The Original Laser Vision Correction Procedure
Photorefractive keratectomy (PRK) was the first widely adopted excimer laser vision correction procedure.
Unlike LASIK, PRK does not require a corneal flap. Instead, the surface epithelium is removed before laser reshaping.
Typical candidates:
- Age: 18 and older.
- Nearsightedness: commonly up to −6.00 to −8.00 D.
- Farsightedness: generally lower to moderate amounts.
- Astigmatism: commonly up to 3.00–4.00 D.
PRK is particularly useful for patients with thinner corneas, certain occupational requirements, or lifestyles involving potential eye trauma. Its principal disadvantage is slower visual recovery and greater discomfort during the first several days. PRK remains an important procedure, although it represents a minority of laser vision corrections.
4. SMILE: Small-Incision Laser Vision Correction
SMILE (Small Incision Lenticule Extraction) was FDA-approved in 2016. Rather than removing tissue with an excimer laser, SMILE uses a femtosecond laser to create a small disc of tissue, called a lenticule, which is removed through a small incision.
Typical candidates:
- Age: 22 and older.
- Nearsightedness: approximately −1.00 to −10.00 D.
- Astigmatism: up to approximately 3.00 D under established U.S. indications.
SMILE avoids creating a LASIK flap and may produce fewer short-term dry-eye symptoms in some patients.
Its limitations include less flexibility for customized optical treatments and enhancements, although technology continues to improve. SMILE and related lenticule extraction procedures are gaining popularity internationally.
5. EVO ICL: One of the Fastest-Growing Categories
EVO ICL (Implantable Collamer Lens) represents an important evolution in refractive surgery.
Instead of permanently removing corneal tissue, EVO ICL places a specially designed lens behind the iris and in front of the natural crystalline lens. Originally considered primarily for patients with high myopia, EVO ICL is increasingly being considered for moderate prescriptions as well.
Current U.S. indications:
- Age: 21–60, following an FDA age expansion in February 2026.
- Nearsightedness: −3.00 to −20.00 D. The lens can treat up to about -15.00, but at SharpeVision we have treated up to -20 using EVO ICL followed by LASIK
- Astigmatism: 1.00–4.00 D with the toric EVO ICL.
EVO ICL offers several advantages: preservation of corneal tissue, excellent optical quality, removability, and suitability for many patients whose corneas make laser vision correction less desirable.
Importantly, patients with prescriptions around −3.00 to −6.00 D may also consider EVO ICL, rather than assuming it is exclusively for extremely high myopia.
The procedure does require intraocular surgery and carries risks including cataract formation, pressure elevation, infection, and lens-sizing complications. By February 2026, STAAR Surgical reported selling more than 4 million ICLs worldwide since the technology’s introduction. In Japan, ICL has reportedly captured more than half the refractive surgery market, and in China up to 80% (personal communication of Dr. Sharpe). In the United States, EVO ICL is gaining share, although LASIK remains more common overall.
6. Refractive Lens Exchange: Vision Correction After 45
Refractive lens exchange (RLE) involves replacing the natural crystalline lens with an artificial intraocular lens before a visually significant cataract develops. It is essentially the same surgical technique as cataract surgery, performed primarily to correct refractive error and presbyopia.
Typical candidates:
- Age: approximately 45–65, depending on the individual.
- Nearsightedness: low to high prescriptions.
- Farsightedness: especially moderate to high hyperopia.
- Presbyopia: patients seeking reduced dependence on reading glasses.
Modern multifocal, trifocal, extended-depth-of-focus, and other advanced lenses can reduce dependence on glasses at multiple distances.
RLE permanently eliminates the possibility of developing a cataract, because the natural lens has already been removed. However, it also eliminates any remaining natural accommodation and introduces intraocular surgical risks, including retinal detachment, particularly in highly myopic patients. Reliable annual RLE-only procedure totals are difficult to establish because many databases combine RLE with cataract surgery.
7. Premium Cataract Surgery: The Largest Growth Opportunity
Cataract surgery is among the most frequently performed operations in medicine. Traditional cataract surgery replaces the cloudy natural lens with a clear artificial lens, often correcting distance vision while leaving patients dependent on glasses for reading. Premium cataract surgery goes further, incorporating technologies such as:
- Toric lenses for astigmatism.
- Multifocal and trifocal lenses.
- Extended-depth-of-focus lenses.
- Light Adjustable Lenses.
Patients are typically in their 60s, 70s, or 80s, although cataracts can develop earlier. Premium lens adoption is increasing as patients seek greater spectacle independence. According to Market Scope estimates, U.S. premium IOL penetration increased from approximately 20% in 2024 to 21% in 2025. Worldwide cataract surgery volume is projected to exceed 39 million procedures annually by 2030.
8. Which Procedures Are Most Popular?
A multicenter study of 18 refractive surgery practices, examining 1,866 eyes treated in 2023, reported the following distribution:
Procedure Share
LASIK 65.5%
EVO ICL / ICL 13.3%
PRK 12.1%
Lenticule extraction, including SMILE 8.6%
RLE Less than 1%
These percentages describe the participating practices, not the entire U.S. or worldwide market. Premium cataract surgery was not included. Nevertheless, the findings illustrate an important trend: LASIK remains the largest category, while lens-based procedures are becoming increasingly important.
9. Procedures That Have Come and Gone
Refractive surgery has experienced its share of innovations that ultimately failed to become lasting mainstream treatments.
Radial keratotomy (RK): Popular in the 1980s, RK used radial corneal incisions to flatten the cornea. Long-term instability, progressive hyperopic shifts, and fluctuating vision largely ended its use. We still commonly use a technique called LRI (limbal relaxing incisions) for small degrees of astigmatism. LRI can be done manually, but at SHARPEVISION we use LRI as part of FLACS (femtosecond laser assisted cataract surgery) where a laser makes 10 to 35° arcuate incisions circumferentially at the edge of the cornea. FLACS also makes the main cataract, side port incision, a circular capsular incision, and divides the nucleus of the cataract all with laser. Much more precise and reproducible than can be done manually.
Conductive keratoplasty (CK): Radiofrequency energy was used to steepen the cornea, primarily for low hyperopia and presbyopia. Regression limited its long-term appeal.
Raindrop corneal inlay: Designed to improve near vision, Raindrop was recalled after concerns about corneal haze and scarring.
KAMRA corneal inlay: A small-aperture implant intended to improve reading vision. Although effective for some patients, visual symptoms, inflammation, and other limitations contributed to its discontinuation.
These experiences remind us that successful refractive surgery requires more than impressive early results. Long-term safety, stability, and quality of vision matter enormously.
10. What’s Next in Refractive Surgery?
Several technologies may shape the next decade:
Next-generation lenticule extraction: SMILE Pro, SILK, CLEAR, and related platforms are expanding the options for flapless corneal correction.
More personalized laser treatments: Ray-tracing, improved diagnostics, and artificial intelligence may help surgeons correct more complex optical imperfections.
Advanced intraocular lenses: Improved multifocal, extended-depth-of-focus, adjustable, and potentially accommodating lens technologies aim to deliver more natural vision across multiple distances.
Restoring accommodation: Researchers are investigating ways to restore the eye’s natural focusing ability rather than simply creating multiple focal points. These approaches remain investigational but could eventually transform presbyopia treatment.
The Bottom Line: The Best Procedure Is the One That Fits Your Eyes
The future of refractive surgery is not about one procedure replacing all the others. LASIK remains an excellent option for many patients. PRK is still an important technique after 31 years in the US. SMILE provides another approach to laser vision correction- in my opinion, it’s still inferior to LASIK, but reasonably good to keep developing. EVO ICL expands possibilities for moderate and high myopia-one of its best advantages short term is that there is no procedure relate to dryness except perhaps a little irritation from the medicated drops. The long-term advantage in my opinion is that it seems significantly more stable than LASIK. That is, sometimes LASIK patients come back 3 to 10 years later and need a touchup. I believe that risk is somewhere around 10% over 10 years, whereas with the EVO ICL I believe it is around 2% over 10 years. RLE and premium cataract surgery offer increasingly sophisticated solutions for aging eyes.
At SHARPEVISION MODERN LASIK & LENS, we have been blessed to be able to offer the full spectrum of procedures so that we can listen to your hopes and expectations, and realistically offer a procedure based on your anatomy, age, and amount of prescription, to help you make the best choice for you. If we were only a LASIK practice, then we would just do LASIK on everyone, and I don’t believe that’s the best for everyone.
It’s an amazing technological world; we welcome the chance to help you see better, and make your life better, through clear uncorrected vision

Dr. Matthew R. Sharpe
